In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS, Nektar build off of 2016 trial collaboration, sign official immuno-oncology deal; Deal ends after poor data analyses

Executive Summary

Stemming from a September 2016 clinical trial collaboration testing the combination of Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and Nektar Therapeutics' NKTR214 (bempegaldesleukin), the companies have now signed an agreement that lays out an official deal with cost and profit splits, as well as commercialization rights.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Trial Collaborations

Related Companies